Also Ben Sessa got a mention - Ran the first clinical study in Australia and has been working with psychedelics for 15 years
He is on our clinical advisory board
I know were in good hands with the clinical team
The only thing I am worried about is what protection do we have for the MDMA analogues,
"VANCOUVER, BC, Feb 23, 2023 /GlobeNewswire/ PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6 Novel Chemical Entities(NCEs). The application claims priority to and benefit of a United States provisional patent application filed on August 20, 2021.This PCT application disclosed novel compositions of MDMA and analogs thereof, which may be used to alleviate the known side effects of MDMA while retaining its efficacy."
Keep in mind Dr Piggott has been working with these MDMA analogues for over 10 years, so where do we stand from a patent protection point of view?
Ann: Webinar Presentation, page-11
Add EMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.001(1.72%) |
Mkt cap ! $24.13M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.9¢ | 5.6¢ | $1.638K | 28.68K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 622 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 11378 | 1 |
View Market Depth
| Last trade - 15.31pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.8¢ |
Change
0.001 ( 1.75 %) |
||||
| Open | High | Low | Volume | ||
| 5.8¢ | 5.8¢ | 5.8¢ | 750 | ||
| Last updated 13.36pm 30/05/2024 ? | |||||
| EMD (ASX) Chart |